SNY Articles, Sanofi - From 01/10/24

French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in a...

Tuesday, China's National Medical Products Administration approved AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA's (...

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies ar...

First Wave BioPharma, Inc. (NASDAQ: FWBI) shares are skyrocketing Wednesday after the company entered a non-binding term sheet to sell its Nic...

MeiraGTx Holdings plc (NASDAQ: MGTX) on Thursday announced an asset purchase agreement with Janssen Pharmaceuticals Inc, a Johnson&n...

Sanofi SA (NASDAQ: SNY) is discontinuing the global clinical development program of tusamitamab ravtansine.  The decision is ba...

First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combine...

Sanofi SA (NASDAQ: SNY), DNDi, and the HAT-r-ACC consortium announce that the European Medicines Agency’s (EMA) Committee for ...

Sanofi SA (NASDAQ: SNY) said it is terminating the licensing agreement for Maze Therapeutics Inc.'s treatment for a rare genetic...

Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd, ...